| Id: | acc4898 |
| Group: | 2sens |
| Protein: | STAT3 |
| Gene Symbol: | Stat3 |
| Protein Id: | P42227 |
| Protein Name: | STAT3_MOUSE |
| PTM: | phosphorylation |
| Site: | Tyr705 |
| Site Sequence: | EADPGSAAPYLKTKFICVTPT |
| Disease Category: | Immune system diseases |
| Disease: | Psoriasis |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | Tofacitinib |
| Drug Info: | "Tofacitinib is a Janus kinase (JAK) inhibitor. It is used in the treatment of certain inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis." |
| Effect: | modulate |
| Effect Info: | "Tofacitinib inhibits the phosphorylation of STAT3 in keratinocytes, thereby alleviating psoriatic-like dermatitis, suggesting the crucial role of the STAT3 signaling pathway in skin pathology." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 34626614 |
| Sentence Index: | 34626614_7-8 |
| Sentence: | "Moreover, psoriasis-like dermatitis inversely associated with type 1 immune gene products, especially CXCL10, whereas CXCL10 limited psoriasis-like dermatitis, suggesting that KC STAT3 signaling promoted psoriasis-like dermatitis by restricting downstream CXCL10 expression. Finally, treatment of mice with the pan-Jak inhibitor, tofacitinib, reduced psoriasis-like dermatitis and epidermal STAT3 phosphorylation." |
Sequence & Structure:
MAQWNQLQQLDTRYLEQLHQLYSDSFPMELRQFLAPWIESQDWAYAASKESHATLVFHNLLGEIDQQYSRFLQESNVLYQHNLRRIKQFLQSRYLEKPMEIARIVARCLWEESRLLQTAATAAQQGGQANHPTAAVVTEKQQMLEQHLQDVRKRVQDLEQKMKVVENLQDDFDFNYKTLKSQGDMQDLNGNNQSVTRQKMQQLEQMLTALDQMRRSIVSELAGLLSAMEYVQKTLTDEELADWKRRQQIACIGGPPNICLDRLENWITSLAESQLQTRQQIKKLEELQQKVSYKGDPIVQHRPMLEERIVELFRNLMKSAFVVERQPCMPMHPDRPLVIKTGVQFTTKVRLLVKFPELNYQLKIKVCIDKDSGDVAALRGSRKFNILGTNTKVMNMEESNNGSLSAEFKHLTLREQRCGNGGRANCDASLIVTEELHLITFETEVYHQGLKIDLETHSLPVVVISNICQMPNAWASILWYNMLTNNPKNVNFFTKPPIGTWDQVAEVLSWQFSSTTKRGLSIEQLTTLAEKLLGPGVNYSGCQITWAKFCKENMAGKGFSFWVWLDNIIDLVKKYILALWNEGYIMGFISKERERAILSTKPPGTFLLRFSESSKEGGVTFTWVEKDISGKTQIQSVEPYTKQQLNNMSFAEIIMGYKIMDATNILVSPLVYLYPDIPKEEAFGKYCRPESQEHPEADPGSAAPYLKTKFICVTPTTCSNTIDLPMSPRTLDSLMQFGNNGEGAEPSAGGQFESLTFDMDLTSECATSPM
Select PDB:
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 705 | U | Neurofibromatosis | Phosphorylation | 23318430 |
| Y | 705 | U | Squamous cell carcinoma | Phosphorylation | 19934324 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
